Company History

SureAdhere’s roots date back to 2009, when co-founder Dr. Richard Garfein and his team at the University of California San Diego (UCSD) developed a novel smartphone application and demonstrated proof-of-concept for using asynchronous video directly observed therapy (VDOT) as an alternative to resource-intensive in-person DOT for supporting medication adherence among patient treated for tuberculosis (TB) through health departments in San Diego, California and Tijuana, Mexico. As a UCSD Pre-Doctoral Fellow prior to SureAdhere’s founding in 2015, Dr. Kelly Collins (SureAdhere CEO) spent five years learning from TB Control Programs and their patients while using VDOT in practice. She has translated that unique knowledge into a superb, client-centered product.  SureAdhere’s application has subsequently been implemented in seventeen states across the U.S., Mexico, the United Kingdom, Vietnam, Uganda, the Philippines, Haiti, Ukraine, and Kyrgyzstan. The SureAdhere team is working to make VDOT available to TB care providers worldwide to stem the epidemic of drug resistant TB, prevent TB transmission and save lives. 


"Our mission is to provide health officials, health care providers and researchers around the globe with a proven, cost effective, and simple remote method of supporting medication adherence where compliance is crucial."


Leadership Team

KELLY COLLINS, PHD, MPH

President & CEO

Trained at UC San Diego in Global Public Health, Dr. Collins was a key member of the research team who evaluated VDOT around the world. Her career has focused on developing and assessing mHealth interventions among vulnerable populations in the U.S. and Mexico, and she has vast experience implementing VDOT in TB control programs both domestically and abroad.

RICHARD GARFEIN, PHD, MPH

Chief Science Officer, and Co-founder

UC San Diego Professor of Medicine, infectious disease epidemiologist and VDOT pioneer, Dr. Garfein is an internationally recognized expert in the field of tuberculosis epidemiology, diagnostics and treatment adherence. He was trained at the Johns Hopkins University School of Public Health and the Centers for Disease Control and Prevention.